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Background: Novel, in silico-designed anticancer compounds were synthesized in our laboratory namely, 2-ethyl-3-O-
sulphamoyl-estra-1,3,5(10),15-tetraen-17-ol (ESE-15-ol) and 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-16).
These compounds were designed to have improved bioavailability when compared to their source compound,
2-methoxyestradiol. This theoretically would be due to their increased binding affinity to carbonic anhydrase II,
present in erythrocytes. Since the novel compounds under investigation are proposed to be transported within
erythrocytes bound to carbonic anhydrase II, the morphological effect which they may exert on whole blood
and erythrocytes is of great significance. A secondary outcome included revision of previously reported procedures for
the handling of the whole blood sample.
The purpose of this study was twofold. Firstly, the ultrastructural morphology of a healthy female’s erythrocytes was
examined via scanning electron microscopy (SEM) after exposure to the newly in silico-designed compounds.
Morphology of erythrocytes following exposure to ESE-15-ol and ESE-16 for 3 minutes and 24 hours at 22°C were
described with the use of SEM. The haemolytic activity of the compounds after 24 hours exposure were also determined
with the ex vivo haemolysis assay. Secondly, storage conditions of the whole blood sample were investigated by
determining morphological changes after a 24 hour storage period at 22°C and 37°C.
Results: No significant morphological changes were observed in the erythrocyte morphology after exposure to
the novel anticancer compounds. Storage of the whole blood samples at 37°C for 24 hours resulted in visible
morphological stress in the erythrocytes. Erythrocytes incubated at 22°C for 24 hours showed no structural
deformity or distress.
Conclusions: From this research the optimal temperature for ex vivo exposure of whole blood samples to
ESE-15-ol and ESE-16 for 24 hours was determined to be 22°C. Data from this study revealed the potential of
these compounds to be applied to ex vivo study techniques, since no damage occurred to erythrocytes ultrastructure
under these conditions. As no structural changes were observed in erythrocytes exposed to ESE-15-ol and ESE-16, further
ex vivo experiments will be conducted into the potential effects of these compounds on whole blood. Optimal
incubation conditions up to 24 hours for whole blood were established as a secondary outcome.
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In our laboratory novel, in silico-designed anticancer
compounds namely, 2-ethyl-3-O-sulphamoyl-estra-1,3,
5(10),15-tetraen-17-ol (ESE-15-ol) and 2-ethyl-3-O-
sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-16) were
recently synthesized [1]. The aim of the compounds’
design was not only to increase potency, but also to
improve their bioavailability when compared to their source
compound, 2-methoxyestradiol (2ME) [1]. Improved bio-
availability was achieved with an addition of a sulphamoy-
lated group to the compound which increases their binding
affinity to carbonic anhydrase II (CAII) present in erythro-
cytes, thus bypassing the first pass of liver metabolism [1-3].
Increased anticancer potency was achieved with modifica-
tions at positions 3 and -17 of the compounds [4-9].
The antiproliferative influence of these compounds has
been demonstrated on various cancer cell lines, particularly
various breast and cervical cancer cell lines [1-3]. They
were shown to suppress microtubule dynamics, causing mi-
totic spindle disruption, inhibition of cancer cell prolifera-
tion and subsequently induce cell death in vitro [1-3,10,11].
Additionally, the compounds inhibit the activity of carbonic
anhydrase IX (CAIX), an enzyme that is over expressed in
a variety of tumours and is known to promote acidification
of the tumour microenvironment [12,13]. The acidic envir-
onment, in turn, plays a role in promoting actions of
growth factors and proteases involved in tumor progression
[1]. In vitro results led to the ex vivo investigation of the in-
fluence of these two novel compounds on the morphology
of platelets and whole blood.
In order to investigate the above-mentioned, previ-
ously reported literature procedures for storage of whole
blood (WB) were revisited. WB is a controversial subject
since temperature and length of storage impact on diag-
nostic markers including morphology, enzyme activity,
haemolysis, membrane loss and platelet activation when
determining possible pathophysiology [14-16]. Some re-
searchers believe that WB can only be stored at room
temperature for a maximum of 8 hours due to concerns
over bacterial contamination, loss of 2,3-diphosphoglyce-
rate (2,3-DPG) in erythrocytes, as well as preservation of
Factor (F) VIII content in plasma [16]. It is recom-
mended to cool blood to 4°C if it must be stored longer
than 8 hours before processing or separation into separate
components [16]. This, however, renders blood samples
unsuitable for platelet preparation when determining cell
numbers and pathological conditions [16].
Van der Meer et al. reported that WB can be stored at
room temperature for up to 24 hours and this may re-
duce the risk of bacterial contamination and improve
platelet yield and quality [16]. In addition, Benson &
Skaar reported that WB stored at room temperature
showed no signs of erythrocyte lysis nor significant alter-
ation of plasma microDNA [14].Erythrocytes are regarded as a reliable model for the
study of oxidative stress [17,18]. Their morphological
changes can be recorded as indicators of oxidative stress,
since erythrocytes are exposed to various adverse condi-
tions including gas exchange where cells are exposed to
hydroxyl radicals and inflammatory processes they are
highly susceptible to oxidative stress [17,18]. Storage of
WB may affect erythrocyte morphology, since pH, gas-
ses, bicarbonate and 2,3-DPG concentrations may be al-
tered [15,16].
The purpose of this study was to examine the external
morphology of a healthy female’s erythrocytes using scan-
ning electron microscopy (SEM) and the ex vivo haemolysis
assay after exposure to newly in silico-designed potential
anticancer drugs. A secondary outcome of the study was to




Whole blood was stored at 22°C and 37°C respectively
to determine the optimal temperature at which erythro-
cytes retain normal morphology. Erythrocytes show normal
morphology at 22°C when compared to 37°C, thus 22°C
was selected for subsequent experiments. The morphology
of erythrocytes (Figure 1A and C) at 37°C was clearly af-
fected, indicating signs of stress including formation of
extended projections, alteration of surface membrane
structure to more bulbous structure and lengthening
of erythrocytes. Erythrocytes exposed at 22°C (Figure 1B
and D) showed normal biconcave structure of erythrocytes
with no lengthening or blebbing.
Immediate cytotoxicity
Figure 2 indicates SEM images of erythrocytes after being
exposed to ESE-15-ol and ESE-16 and the relevant control
for 3 min (Figure 2C and D) and 24 hours (Figure 2E and
F) at 22°C. Results revealed no significant morphological
changes in erythrocytes after 3 min and 24 hours in WB
samples exposed to the compounds and the control re-
spectively. This indicates that the compounds do not
cause an immediate or delayed stress reaction visible in
the erythrocyte membrane of a healthy individual.
Ex vivo erythrocyte haemolysis assay
The % of haemolysis for all control and exposed samples
is represented in Figure 3. The results indicate that all
samples exhibit less than 1% haemolytic activity. This
data corresponds with SEM results showing that these
novel compounds do not affect the morphology of the
erythrocytes and have no cytotoxic effects.
This study investigated the possible immediate cyto-
toxicity which occurs within 3 min of exposure to the
unique ESE-15-ol and ESE-16 anticancer compounds,
Figure 1 SEM images of red blood cells after exposure at 37°C and 22°C for 22 hours. Untreated control erythrocytes at 37°C (A) and 22°C
(B). Vehicle control erythrocytes at 37°C (C) and 22°C (D). ESE-15-ol-treated erythrocytes at 37°C (E) and 22°C (F). ESE-16-treated erythrocytes at
37°C (G) and 22°C (H).
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exposure for 24 hours at room temperature (22°C). Re-
sults revealed that there was no significant damage to
the structure of erythrocyte membranes when exposed
to ESE-15-ol and ESE-16. This was also seen in the
ex vivo haemolysis assay results which indicated the
compounds had no significant haemolytic activity after
24 hours exposure. DMSO-treated erythrocytes at a con-
centration of 1% showed morphological alteration as ex-
pected for a positive control. However there was no
statistically significant increase in haemolytic activity in-
dicating that this concentration of DMSO does not rup-
ture erythrocyte membranes.In addition, WB stored at room temperature (22°C)
showed significantly less morphological changes when
compared to samples stored at 37°C. This is similar to
the findings of Van der Meer et al. (2011) who demon-
strated that the quality of WB stored at room temperature
overnight was comparable to that of freshly processed WB
[16]. In addition, Baumgarten et al. showed a decrease in
platelet counts, as well as platelet aggregation when blood
was stored at 4°C since platelets aggregate at low tempera-
tures which results in the disintegration of the platelets
[19]. It has also been suggested that storage of blood at
room temperature provides more suitable haemostatic
function for ex vivo experiments, since preservation of
Figure 2 SEM images of erythrocytes after 3 min exposure at 22°C. (A) erythrocytes of untreated WB sample, (B) erythrocytes of WB sample
treated with DMSO as vehicle control, (C) erythrocytes of WB sample treated with ESE-15-ol and (D) erythrocytes of WB sample treated with
ESE-16 and (E) erythrocytes of WB sample treated with 1% DMSO (v/v) as positive control. No significant morphological changes in the
erythrocytes treated with the compounds and controls were observed after 3 min.
Figure 3 Ex vivo haemolysis assay. The haemolytic activity of
ESE-15-ol- and ESE-16-treated erythrocytes was found to be less
than 1% as observed in the control samples. Standard deviation
was indicated on the graph for 3 technical repeats.
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temperature [19].
Stander suggested that ESE-15-ol and ESE-16 revers-
ibly bind to carbonic anhydrase II (CAII) in red blood
cells in order to bypass the first pass metabolism in the
liver due to release into the blood stream from CAII,
resulting in increased bioavailability [1]. Since these
compounds are hypothesised to be carried in the blood
bound to CAII, the effect of these compounds on the
morphology of erythrocytes is significant and results in-
dicate the normal morphology of erythrocytes when ex-
posed to these compounds which suggest future in vivo
studies to be viable.
Conclusions
This case study reports on the influence of ESE-15-ol
and ESE-16 on the morphology of erythrocytes ex vivo.
Results indicate that these compounds do not cause
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whole blood for 3 min or 24 hours at room temperature
(22°C). Ex vivo research may be superior when con-
ducted at room temperature (22°C), since samples ex-
posed at these temperatures showed less change in
morphological structure when compared to samples in-
cubated at 37°C. Data from this study reveal the poten-
tial of these compounds to be applied to ex vivo study
techniques at 22°C. Future ex vivo investigations will
focus on the other components within whole blood
when exposed to ESE-15-ol and ESE-16.
Methods
Materials
Ethylene-diamine-tetra-acetic acid (EDTA) tubes and needles
were acquired from Transpharm (Gauteng, SA). Phosphate-
buffered saline (PBS) was purchased from Gibco-BRL
(Invitrogen, Carlsbad, CA, USA). Dimethyl sulphoxide
(DMSO) was supplied by Sigma-Aldrich Co (St. Louis,
USA).
Preparation of compounds
Since ESE-15-ol and ESE-16 were in silico-designed at
the Bioinformatics and Computational Biology Unit, De-
partment of Biochemistry, University of Pretoria, South
Africa and are not commercially available. Synthesis of
ESE-15-ol and ESE-16 was done by Ithemba Pharmaceu-
ticals (Pty) Ltd (Modderfontein, Midrand, South Africa).
ESE-15-ol and ESE-16 were dissolved in DMSO and the
final concentration did not exceed 0.01% (v/v) in subse-
quent experiments [1]. Blood samples were exposed to
0.18 μM of ESE-15-ol and ESE-16 [1]. This concentra-
tion was selected since our laboratory established previ-
ously that ESE-15-ol and ESE-16 inhibited cell growth
by 50% (GI50) at this concentration after 24 hours at 37°C
in vitro [1]. Control samples included DMSO at a concen-
tration of 0.01% as vehicle control, DMSO at a concentra-
tion of 1% (v/v) as a positive control and untreated WB as
negative control [20].
Method
Study design and sampling method
To conduct the case study, blood was collected from a
healthy female individual aged 45 years who does not
smoke or does not use any medication [21]. As breast
cancer is the second leading cause of mortality of fe-
males globally and first leading cause in sub-Saharan
Africa with poor survival rates, a female participant was
chosen for this study, to determine possible future appli-
cations [22-24]. Even though the compounds tested in
this study are derived from 17β-estradiol, the com-
pounds do not bind selectively to estrogen receptors,
yet rather to CAII and any hormonal fluctuations in afemale participant would not have an effect on the
drugs activity or binding [1-3].
The participant met the following exclusion criteria:
chronic or acute illnesses, autoimmune diseases, heredi-
tary diseases, hypertension, contraceptives, or smoking.
Informed consent was obtained from the individual be-
fore collection of blood in EDTA tubes and blood sam-
ples were collected after an 8 hour period of fasting
between 08:00-09:00 am. Platelet-rich plasma (PRP) was
obtained by centrifuging the blood at 1000 rpm for 2 min
and collecting plasma from the separated blood [25].
A time- and temperature-based study was conducted
with the use of SEM to assess morphological changes on
WB by exposing WB to ESE-15-ol and ESE-16 at time
intervals of 3 min to determine possible immediate tox-
icity and 24 hours to determine effects of the com-
pounds at this time interval. The latter is equivalent to
the exposure time used for cancer cell lines in our la-
boratory [1-3]. WB samples were exposed for 24 hours
at 22°C and 37°C respectively to determine optimal
temperature at which the membrane morphology of
erythrocytes remained normal and at which future
ex vivo studies exposure to ESE-15-ol and ESE-16 may
occur.
Scanning electron microscopy
Morphology of erythrocytes within WB samples exposed
to ESE-15-ol and ESE-16 at time intervals of 3 min (to
determine possible immediate toxicity) and 24 hours (to
determine effects at this time interval equivalent to ex-
posure of cancer cell lines) was determined via SEM.
Morphology of WB samples when exposed to ESE-15-ol
and ESE-16 for 24 hours at 22°C and 37°C respectively
was also studied. Samples were viewed with the Zeiss
ULTRA plus FEG-SEM at the Microscopy and Micro-
analysis Unit of the University of Pretoria, Pretoria,
South Africa.
Ex vivo samples were prepared on glass plates with
10 μl (107 platelets/ml) WB as a control, 10 μl WB ex-
posed to ESE-15-ol and 10 μl WB exposed to ESE-16 re-
spectively [25]. Glass plates with ex vivo samples were
placed in 6 well plates and left to dry slightly, after
which the samples were washed for 20 min in a 50%
PBS: 50% distilled H2O solution. Samples were fixed
with gluteraldehyde and PBS for 30 min and washed 3
times in PBS for 3 min each for subsequent secondary
fixation in osmium for 15 min. Samples were washed 3
times each for 3 min and dehydrated for 3 min each in
increasing concentration of ethanol, 30%, 50%, 70%, 90%
and three times in 100% ethanol [25]. Samples were critic-
ally dried, mounted and carbon-coated and were viewed
using the Zeiss ULTRA plus FEG-SEM (Carl Zeiss (Pty)
Ltd, Johannesburg, South Africa). Qualitative SEM images
were obtained from 3 independent experiments repeated
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to represent all 3 repeats.Ex vivo erythrocyte haemolysis assay
To quantitatively assess the membrane disrupting poten-
tial of ESE-15-ol and ESE-16 on erythrocytes, an ex vivo
erythrocyte haemolysis assay was performed.
When the erythrocyte membrane is destroyed, haemo-
globin is released [26]. The haemoglobin can then be
isolated from the erythrocytes and spectrophotometric-
ally quantified at an absorbance of 540 nm [26,27].
Whole blood samples were placed in 96 well plates
(200 μl of blood sample per well) and exposed to the
compounds or the various controls as discussed above.
The samples were then incubated at 22°C for 24 hours.
After the incubation period, 20% Triton X-100 was added
to designated samples as a positive control for erythro-
cytes heamolysis and incubated at 22°C for 10 min. Sam-
ples (200 μl) were then transferred to eppies and diluted
ten times with PBS (pH 7.4). Samples were spun down at
10 000 × g for 10 min. Supernatant (100 μl) was trans-
ferred to a clean 96-well plate and absorbance determined
at a wavelength of 540 nm with the use of an ELx800
Universal Microplate Reader (Bio-Tek Instruments Inc.
Vermont, USA). For data analysis the background ab-
sorbance value was subtracted from all sample values
and the average absorbance of the positive control
samples were used to normalize all experimental data
points to this mean absorbance value, representing
100% hemolysis. To calculate % hemolysis in each well
relative to positive control, their values were multi-
plied by 100% [26,27]. Results were obtained from 3
technical repeats for the participant.Ethics
Ethical clearance for the collection of blood was ob-
tained from The Research Ethics Committee, Faculty
Health Sciences, University of Pretoria which complies
with ICH-GC.P guidelines (Ethics clearance number:
289/2013).
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